CLUE
17.11.2021 01:03:12 CET | Business Wire | Press release
Clue, a SaaS platform for managing investigations, today announced growth investment of £5 million from Frog Capital, a leading investor in European scale-up software. Demand for Clue has more than doubled over the last two years, driven by co-owners Clare Elford, CEO, and Thomas Drohan, CCO. From its roots in policing, the platform is now used across government, private and non-profit sectors to investigate cyber-crime, fraud, child protection, corruption, environmental crime, cheating in sports and much more. Clare and Thomas are joined on the board of directors by Nick Harber, CFO; Mike Reid, Senior Partner at Frog Capital; and Adam Hale, Chair of the ScaleUp Institute, as Chairman.
Clare Elford, CEO, said: “The world of intelligence and investigations is no longer constrained to policing, there is much wider application. Organisations are under growing scrutiny, finding themselves more susceptible to threats and with a much greater duty of care towards the vulnerable.
“Clue has productised decades of investigation expertise into a platform that empowers intelligence officers and investigation experts to achieve successful outcomes. So many of those dedicated to preventing harm and seeking justice have to deal with an overwhelming volume and complexity of data. Still reliant on legacy systems, or even spreadsheets, this is a sector primed for digital transformation.”
Thomas Drohan, CCO, said “With this investment, we will strengthen the capabilities of the platform with further AI and ML capability, automation, data insights and business intelligence, while continuing to support and build our user community. Frog have a formidable track record, with an impressive team who we are looking forward to working with to deploy the Scale-up Methodology and drive business growth and a solution to better serve the market.”
Mike Reid, at Frog Capital who joins Clue’s board said: “Across the industries that Clue serves there's a deep-rooted frustration at the lack of good enough tech to allow people to do their investigative work as efficiently and thoroughly as they need. For too long there's been a staggering underinvestment in how investigations are done, resulting in missed opportunities and slow outcomes for hardworking investigative teams and the people they serve.
“Clue's technology is genuinely delivering very significant clients a step change in how they manage and resolve incredibly complex and sensitive investigation cases. With Frog’s investment and experienced team of operators, Clue can accelerate their incredibly positive organisational and, critically, social impact in the key fields of policing, child welfare, financial crime amongst many others.”
Clue’s new Chairman, Adam Hale, said: “'I first met Clare and Thomas just before the pandemic and was really impressed with what they had built and the magnitude of customer problem that Clue solves. Since then, working with the ScaleUp Group, they have raised value-added SaaS growth investment from Frog Capital. I have known Frog for many years and am delighted to become part of their portfolio. I'm also really excited to work with Nick Harber again. I studied Computer Science in Bristol in the 80s and love coming back to a city set to support high growth organisations such as Clue.
“Now is the 'end of the beginning' for Clue and the start of the path to market leadership. From speaking to customers, I can hear how invaluable Clue is to them. There is so much opportunity and I'm thrilled to be part of it.”
About Clue
Clue is a cloud-based investigation case management and intelligence platform that enables organisations to prevent harm and secure justice by building intelligence and quickly progressing investigations in the face of evolving threats, increasing volumes of data, and the need for multi-agency collaboration.
About Frog Capital
Frog Capital is a specialist software Scale-Up Investor in high-growth European software companies and software-enabled businesses at the Scale-Up stage. Frog has a team of in-house operating partners who actively support their portfolio at executive level across the wide range of business challenges they face. Frog has combined over 20 years of experience to create its unique Scale-Up Methodology, which provides a framework defining the major elements of success through the Scale-Up phase.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005095/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom